US Patent 5,703,079: Scope, Claim Analysis, and US Landscape
United States Patent 5,703,079 claims a family of substituted stereodefined alkyl-hydroxy compounds (and pharmaceutically acceptable salts) presented in formula I and several downstream formulas (III and IV), plus fungal treatment uses via composition and method claims.
Based on the text provided, the claim set is anchored on three layers of scope:
1) Core chemical scaffold in formula I with tightly constrained halogen patterning (F and/or Cl) and alkyl-hydroxy substituent definition (C4-C5)
2) Stereochemistry requirements at specified carbons (R/S absolute configuration) in dependent claim territory
3) Use claims that tie the compound class to fungal infections, including oral and parenteral dosing modes
What do the claims cover in chemical scope (Formula I)?
Claim 1 (independent) defines the chemical heart of the patent
Claim 1 is directed to:
- A compound represented by formula I (structure not reproduced in your excerpt, but the variable definitions are)
- Halogen definition at X
- X is independently F or Cl, with either:
- both X are F, or both X are Cl, or
- one X is F and the other is Cl
- R1 definition
- R1 is a straight or branched chain alkyl group (C4 to C5) that is substituted by a hydroxy group
- Also covers:
- the compound and “a pharmaceutically acceptable salt thereof.”
Scope implications (from the provided variable definitions):
- The patent excludes C3 and C6+ alkyl substituents in the R1 position by claim language.
- The patent also excludes hydroxy-substituted alkyls outside C4-C5.
- It allows both homohalogen and mixed halogen patterns for the X substituents (FF, ClCl, and FCl).
Claim 1 does not lock stereochemistry
Claim 1’s provided text does not explicitly require absolute R/S configuration. That constraint appears in dependent claim 2, where specific C-positions marked by asterisk (*) must have defined absolute configurations.
How narrow is the scope in dependent claims (Claims 2-6)?
Claim 2: narrows R1 to a defined menu of hydroxy-substituted C4-C5 structures with absolute stereochemistry
Claim 2 specifies R1 selected from six named structural patterns, each containing a terminal or internal group labeled by *asterisk()** and requiring:
- R4 = OH
- the carbons marked with * have R or S absolute configuration
- each asterisked carbon’s configuration is explicitly constrained by claim language:
- “the carbons with the asterisk(*) have the R or S absolute configuration”
The six R1 options listed are:
--CH(C2H5)CH(R4)CH3 (with asterisk at the stereocenter positions per the excerpt) --CH(C2H5)CH2CH2R4 --(CH2)2--CH(R4)C2H5 --CH(CH3)CH(R4)CH3 --CH(C2H5)CH2R4 --CH(CH3)CH2CH2R4
with R4 = OH.
Scope implications:
- Claim 2 effectively narrows Claim 1 from “any C4-C5 hydroxy alkyl (straight or branched)” to a closed set of enumerated substitution patterns.
- Claim 2 introduces stereochemical control at defined positions (asterisks), which will materially limit both infringement coverage and design-around possibilities.
Claim 3: limits R1 to C4 hydroxy-substituted alkyl
Claim 3 narrows R1 to:
- R1 is a C4 alkyl group substituted by a hydroxy group
Scope implications:
- It removes C5 variants from the Claim 1 class when the claim is asserted specifically as written.
Claim 4: limits R1 to C5 hydroxy-substituted alkyl
Claim 4 narrows R1 to:
- R1 is a C5 alkyl group substituted by a hydroxy group
Claim 5: expands beyond formula I to formula III (R5 and R13 constraints)
Claim 5 claims a compound represented by formula III with:
- R5 is (a defined structure in the excerpt)
- R13 is a hydroxy group
- or a pharmaceutically acceptable salt
Scope implications:
- Claim 5 pulls in at least one additional structural element family via formula III.
- The excerpt does not show the full definition of the variables, but it clearly ties a hydroxyl to R13 and embeds the rest through R5 definition.
Claim 6: further constrains to formula IV with specific R9 substitution and hydroxy in R6
Claim 6 claims:
- compound represented by formula IV
- R9 is either:
--*CH(C2H5)CH(R6)CH3 or--*CH(CH3)CH(R6)CH3
- R6 is OH (or pharmaceutically acceptable salt)
Scope implications:
- This claim is a targeted subset with:
- explicit R6 = OH
- restricted R9 substitution patterns
- stereocenter at the carbon marked by *asterisk()**
What is the therapeutic scope (Claims 7-9)?
Claim 7: composition claim tied to fungal treatment
Claim 7 claims:
- A pharmaceutical composition for treating or preventing fungal infection
- containing an antifungally effective amount of a compound of Claim 1
- plus a pharmaceutically acceptable carrier
Scope implications:
- The active must be within Claim 1’s chemical coverage.
- It is not limited to a specific fungal species, strain, or treatment duration in your excerpt.
- The carrier is conventional and not defined.
Claim 8: method-of-treatment claim for mammalian fungal infections
Claim 8 claims:
- A method of treating and/or preventing fungal infections in a mammal
- comprising administering an antifungally effective amount of a compound of Claim 1
Scope implications:
- The mammalian limitation matters for animal-model use; it is broad for human and veterinary use if “mammal” is treated broadly in practice.
- Dosing is defined only by “antifungally effective amount.”
Claim 9: mode-of-administration specificity
Claim 9 adds:
- composition of Claim 1 where mode of administration is oral or parenteral
Scope implications:
- It blocks some dosing strategies from cleanly falling outside oral/parenteral categories.
- It does not exclude topical or inhaled routes as written, but Claim 9 only covers oral and parenteral as a dependent claim.
Claim dependency map (what depends on what, and what that means for enforcement)
From the excerpt:
- Claim 1: independent chemical (formula I), halogen pattern + R1 C4-C5 hydroxy alkyl + salt.
- Claims 2-4: dependent narrowing of Claim 1
- Claim 2: enumerated R1 patterns + R4 = OH + stereochemical constraint.
- Claim 3: R1 is C4 hydroxy-substituted.
- Claim 4: R1 is C5 hydroxy-substituted.
- Claims 5-6: additional independent-looking structures (formula III and IV), but still within the overall patent’s compound family.
- Claim 7: composition for fungal treatment using compound of Claim 1.
- Claim 8: method of treating/preventing fungal infections in mammal using compound of Claim 1.
- Claim 9: dependent on Claim 7 (composition) and restricts mode to oral or parenteral.
Enforcement consequences:
- The broadest chemical anchor for medical use enforcement is Claim 1, because Claims 7 and 8 require “a compound of claim 1.”
- If an accused product lands outside formula I’s R1 and X definitions, it falls away from the use claims even if it matches Claims 2-6.
- If a product falls within Claim 1 but differs in stereochemistry enumerated in Claim 2, infringement for Claim 2 may fail while Claim 1 could still capture it (unless Claim construction imports stereochemistry from the dependency chain).
How strong is claim scope versus typical design-around strategies?
Halogen design-around (X)
Claim 1 permits three halogen pattern outcomes for the two X positions:
Design-around by moving to other halogens (Br, I) or additional substitution patterns would be outside the explicit “F or Cl” constraint.
Alkyl length design-around (R1 C4-C5)
Design-around by:
- shifting R1 to C3 or C6+
- or using alkyls not “straight or branched chain” (not captured by the claim’s “alkyl group substituted by hydroxy group” language)
would exit Claim 1.
Stereochemistry design-around
Claim 2 and Claim 6 impose stereochemical constraints via asterisks.
Design-around by changing absolute configuration could avoid Claim 2/6 coverage, but may not avoid Claim 1 if Claim 1 itself does not require absolute stereochemistry.
Use design-around
If a competitor targets antifungal activity but claims are limited to:
- “fungal infection” in mammal (Claim 8)
- oral/parenteral (Claim 9 dependent)
they still potentially fall within Claim 7/8 broadly for treatment/prevention if they administer an antifungally effective amount of a Claim 1 compound.
A clean use design-around would require:
- not treating/preventing fungal infection
- or avoiding mammal use (Claim 8)
- or avoiding oral/parenteral (to evade Claim 9 specifically)
US patent landscape implications (what to expect around this patent)
This patent is structurally typical of US chemical-and-use filings: broad chemistry claims for defined substituent patterns paired with medical use claims for antifungal treatment. In the US landscape, patents like this typically face:
- Citation pressure from earlier antifungal chemotypes and close structural analogs in substituted halogenated systems
- Genus-versus-species issues for claim construction where dependent claims enumerate species and introduce stereochemistry
- Potential family extensions around salts, polymorphs, stereoisomer selection, and process improvements
- Competing follow-on filings that aim to move R1 length, relocate hydroxy, or change halogen identity beyond F/Cl
Given only your excerpt of the claim text and no bibliographic data (assignee, filing date, expiration), the only actionable landscape inference that can be made strictly from claim structure is the enforcement hook:
- Any competitor launching an antifungal product that contains a compound matching formula I substitutions and administers it for fungal treatment is directly within Claims 7 and 8, with oral/parenteral inclusion for Claim 9.
Scope summary table (what each claim captures)
| Claim |
Type |
Core chemical element(s) in scope (from excerpt) |
Key constraints |
| 1 |
Independent chemical |
Formula I; X is F or Cl; R1 is straight/branched C4-C5 alkyl with OH; salts |
X restricted to F/Cl combinations; R1 restricted to C4-C5 and hydroxy-substituted |
| 2 |
Dependent chemical |
R1 enumerated structures; R4 = OH; asterisk carbons have specified absolute R/S |
Closed set of R1 patterns; stereochemistry required |
| 3 |
Dependent chemical |
R1 is C4 hydroxy-substituted alkyl |
Fixes chain length to C4 |
| 4 |
Dependent chemical |
R1 is C5 hydroxy-substituted alkyl |
Fixes chain length to C5 |
| 5 |
Chemical claim |
Formula III; R13 = OH; R5 defined |
Locks hydroxyl at R13; depends on formula III variable definitions |
| 6 |
Chemical claim |
Formula IV; R9 is two specified substituted options; R6 = OH |
Two R9 variants; asterisk stereocenter; R6 fixed to OH |
| 7 |
Composition |
Antifungal composition for treating/preventing fungal infection with compound of Claim 1 |
Requires compound-of-Claim-1 and antifungally effective amount; includes carrier |
| 8 |
Method |
Treating/preventing fungal infection in mammal with compound of Claim 1 |
Requires mammal and fungal infection treatment/prevention |
| 9 |
Dependent composition use |
Composition of Claim 1 with mode oral or parenteral |
Restricts administration route to oral/parenteral |
Key Takeaways
- The patent’s medical-use enforcement anchor is Claim 1: composition and method claims require “a compound of claim 1.”
- Claim 1 sets a tight chemical boundary: X = F/Cl only and R1 = hydroxy-substituted straight or branched C4 to C5 alkyl.
- Dependent Claim 2 adds a closed list of R1 structures and imposes absolute stereochemical constraints at asterisked carbons, shrinking coverage for that dependency but not necessarily Claim 1.
- Use claims cover treating and/or preventing fungal infections in mammals and include oral or parenteral administration in Claim 9, strengthening practical infringement risk for systemic antifungal products.
FAQs
1) Does Claim 1 require stereochemistry?
Your excerpt does not state absolute R/S requirements in Claim 1. Absolute configuration appears in dependent Claim 2 (asterisked carbons) and in Claim 6 (asterisked carbon).
2) What is the maximum R1 size allowed under the broadest chemical claim?
R1 in Claim 1 is restricted to C4 to C5 hydroxy-substituted straight or branched alkyl groups.
3) Are both mixed and same halogen patterns allowed?
Yes. Claim 1 allows X to be (F,F), (Cl,Cl), or (F,Cl) because X is “independently” F or Cl with the listed combinations.
4) Do the fungal treatment claims cover composition and dosing?
Yes. Claim 7 covers a composition with an antifungally effective amount and a carrier. Claim 8 covers a method of administering an antifungally effective amount to a mammal. Claim 9 adds oral or parenteral mode.
5) Can a competitor avoid the use claims by changing oral versus topical delivery?
Claim 9 specifically covers oral or parenteral routes, but Claims 7 and 8 as written cover treating/preventing fungal infection without route limitation. Avoiding Claim 9 does not automatically avoid Claims 7 and 8.
References
[1] United States Patent 5,703,079 (claims excerpt provided in the prompt).
